Lilly(Eli) & Co (LLY)

Lilly is a global health care leader that unites caring with discovery to create medicines that make life better for people around the world. It was founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today it remains true to that mission in all its work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.

Company profile

Ticker

LLY

Exchange

NYSE

Website

www.lilly.com

CEO

David Ricks

Incorporated

Indiana

Location

Indiana

Fiscal year end

Dec 31

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Allergan • Abbott Laboratories • Teva- Pharmaceutical Industries • Bristol-Myers Squibb • Viatris • Abbvie • Warner Chilcott ...

Former names

LILLY ELI & CO, LILLY ELI & CO ET AL

SEC CIK

0000059478

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

1096401 B.C. Unlimited Liability Company • Acanthas Pharma, Inc. • Alnara Pharmaceuticals, Inc. • Andean Technical Operations • ARMO Biosciences, Inc. • AurKa Pharma, Inc. • Avid Radiopharmaceuticals, Inc. • CoLucid Pharmaceuticals, Inc. • Compania Farmaceutica Eli Lilly de Centro America S.A. • Dermira, Inc. ...

IRS number

350470950

LLY stock data

1M 1Y 5Y

News

From Benzinga Pro

Devon Energy, Eli Lilly Are CNBC 'Fast Money' Mentions, With Kevin O'Leary Selling These 7 Stocks

19 Aug 22

CNBC’s "Fast Money: Halftime Report" delivers market-moving news to investors.

Eli Lilly Whale Trades For August 18

18 Aug 22

A whale with a lot of money to spend has taken a noticeably bearish stance on Eli Lilly. Looking at options history for Eli Lilly (NYSE:LLY) we detected 15 strange trades.

Here's How Much You Would Have Made Owning Eli Lilly Stock In The Last 10 Years

16 Aug 22

Eli Lilly (NYSE:LLY) has outperformed the market over the past 10 years by 10.36% on an annualized basis producing an average annual return of 22.1%. Currently, Eli Lilly has a market capitalization of $295.32 billion.

Landmark Drug Pricing Reform Bill Passes Congress House

15 Aug 22

Weekend Stock Spotlight: Affirm, SoftBank And How Trump Documents Seizure May Impact Midterms

13 Aug 22

Press releases

From Benzinga Pro

Thinking about trading options or stock in General Motors, 3M, Eli Lilly, UnitedHealth, or General Electric?

19 Aug 22

NEW YORK, Aug. 19, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GM, MMM, LLY, UNH, and GE.

Millions Suffering From Diabetes May Soon See Relief From Some Of The Pain And Expenses Associated

18 Aug 22

By Mark Gilman -- BenzingaSeattle, Washington--News Direct--Americans with diabetes have been relying on insulin injections to manage their illness for decades. Those injections can be painful, expensive and

Thinking about trading options or stock in Lowe's, Progressive, Home Depot, Eli Lilly, or Costco?

17 Aug 22

NEW YORK, Aug. 17, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LOW, PGR, HD, LLY, and COST.

Lilly Announces Leadership Transition in Human Resources and New Chief Commercial Officer for Loxo@Lilly

11 Aug 22

Lilly's Taltz® (ixekizumab) Now Available in New, Citrate-Free Formulation to Reduce Injection Site Pain for Improved Patient Experience

8 Aug 22

Analyst ratings and price targets

Last 3 months

Average target

$361.50

Low target

$341.00

High target

$395.00

Calendar

4 Aug 22

19 Aug 22

31 Dec 22

Financial summary

Financial statements Chart LLY financial data

Quarter (USD)	Jun 22	Mar 22	Dec 21	Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21	Dec 20	Dec 19	Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	2.62B	2.62B	2.62B	2.62B	2.62B	2.62B
Cash burn (monthly)	(no burn)	49.76M	(no burn)	(no burn)	(no burn)	(no burn)
Cash used (since last report)	n/a	83.65M	n/a	n/a	n/a	n/a
Cash remaining	n/a	2.54B	n/a	n/a	n/a	n/a
Runway (months of cash)	n/a	51.0	n/a	n/a	n/a	n/a

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Recent insider trades

LLY insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
15 Aug 22	Alvarez Ralph	Common Stock	Grant	Acquire A	No	No	313.94	36	11.3K	51,771
15 Aug 22	J Erik Fyrwald	Common Stock	Grant	Acquire A	No	No	313.94	32	10.05K	69,560
15 Aug 22	Hedley Mary Lynne	Common Stock	Grant	Acquire A	No	No	313.94	32	10.05K	114
15 Aug 22	Kimberly H Johnson	Common Stock	Grant	Acquire A	No	No	313.94	31	9.73K	1,332
15 Aug 22	Luciano Juan R	Common Stock	Grant	Acquire A	No	No	313.94	45	14.13K	13,954

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

Institutional ownership, Q2 2022

LLY institutional ownership history Ownership history

70.2% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	2340	2280	+2.6%
Opened positions	204	164	+24.4%
Closed positions	144	126	+14.3%
Increased positions	833	865	-3.7%
Reduced positions	863	832	+3.7%

13F shares	Current	Prev Q	Change
Total value	216.27B	192.56B	+12.3%
Total shares	667.04M	673.98M	-1.0%
Total puts	4.55M	4.6M	-1.0%
Total calls	4.28M	4.07M	+5.0%
Total put/call ratio	1.1	1.1	-5.7%

Largest owners	Shares	Value	Change
Vanguard	71.59M	$23.21B	+1.6%
BLK Blackrock	63.75M	$20.67B	-0.4%
PNC PNC Financial Services	52.09M	$16.89B	-0.1%
STT State Street	33.41M	$10.83B	-1.0%
FMR	32.44M	$10.52B	+2.9%
Capital World Investors	28.74M	$9.32B	+28.6%
Primecap Management	28.44M	$9.22B	-1.5%
Wellington Management	23.44M	$7.6B	-13.9%
TROW T. Rowe Price	20.43M	$6.62B	-2.4%
State Farm Mutual Automobile Insurance	17.41M	$5.65B	0.0%

Largest transactions	Shares	Bought/sold	Change
Capital World Investors	28.74M	+6.38M	+28.6%
LGEN Legal & General	0	-6.3M	EXIT
Capital International Investors	4.96M	-3.88M	-43.9%
Wellington Management	23.44M	-3.79M	-13.9%
MS Morgan Stanley	7.5M	+3.53M	+88.8%
Parametric Portfolio Associates	0	-3.24M	EXIT
Capital Research Global Investors	2.91M	+2.91M	NEW
Jennison Associates	10.36M	+2.46M	+31.1%
Fisher Asset Management	5.93M	-1.57M	-20.9%
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main	2.28M	-1.47M	-39.2%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Financial report summary

Management Discussion

Item 2. Management's Discussion and Analysis of Results of Operations and Financial Condition

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: apnea, biologic, branch, BTLA, commenced, compensatory, Concord, depletion, growth, IP, jury, Lebanon, Limerick, Milan, minimize, Mounjaro, network, NRDL, Obstructive, parenteral, permanent, rejected, remedial, Retatrutide, revocation, Rezpegaldesleukin, select, sleep, VBP, verdict

Removed: Aetna, ampullary, arose, aware, back, BI, born, challenging, Connecticut, contamination, covering, deceptive, defend, Dermira, detailed, discontinued, Eagle, Fournier, gangrene, grant, half, handed, healthcare, indemnify, lifetime, NaN, originally, partial, paused, paying, relator, remdesivir, representing, resolve, restricted, resurgent, Separately, settle, settled, Stamford, unlimited, withdrawn, worked, writ

From filing 10-Q 2022 Q2

Financial reports

View all